Signatera Breast Cancer Data Sheet

Signatera Patient Test Sample Report

Natera’s ESG commitment

Natera’s 2021 ESG & Social Responsibility Report

Natera Cyber Security Policy Report

Natera Quality Policy

Panorama Sample Report: High Risk

Panorama Sample Report: Low Risk

Signatera Test Report

Signatera is a bespoke mPCR-NGS assay for detection and quantification of circulating tumor DNA (ctDNA) in the plasma of patients previously diagnosed with cancer.

Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy and identify patients at high risk of recurrence

Tarazona N, Henriksen TV, Carbonell-Asins JA, et al. Oral presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4009